Corolabs

Company Overview

Snapshot

Founded in April 2020 by Asaf Weinberger, Corolabs operated with 1–10 employees, focusing on deep-lung inhalation therapies. The company ceased operations in December 2024.

Business overview

Corolabs specializes in developing inhaled medications combined with a novel delivery system designed to reach the deep lung. The company's aerosol technology produces and delivers sub-micron droplets to the alveoli, enabling localized treatment for lower respiratory diseases and systemic drug delivery. This technology aims to facilitate home-based treatments for conditions traditionally managed in hospital settings via intramuscular or intravenous therapy. Corolabs serves the healthcare and life sciences markets, specifically targeting pharmaceuticals, providers, and patients with solutions for infectious diseases, drug delivery, and medical treatments.

Company Intelligence Q&A

What is Corolabs' primary focus?

Corolabs focuses on developing deep-lung inhalation therapies for infectious diseases, utilizing a novel aerosol technology for targeted drug delivery to the alveoli.

When was Corolabs founded and by whom?

Corolabs was founded in April 2020 by Asaf Weinberger.

What is the current status of Corolabs?

Corolabs ceased to operate in December 2024.

What technology does Corolabs utilize?

Corolabs employs an aerosol technology capable of producing and delivering sub-micron droplets to the deep lung, enabling localized treatment and systemic drug delivery.

What markets does Corolabs aim to serve?

Corolabs aims to serve the healthcare and life sciences markets, including pharmaceuticals, healthcare providers, and patients, by offering home-based treatments for lower respiratory diseases.